NCT03741699View on ClinicalTrials.gov

Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH)

PHASE3CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 18, 2019

Primary Completion Date

May 11, 2024

Study Completion Date

May 11, 2024

Conditions
Infertility, Female
Interventions
DRUG

Pre-treatment with rLH (Luveris 75 IU),

Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)

Trial Locations (3)

28023

IVI Madrid, Madrid

30007

IVI Murcia, Murcia

03015

IVI Alicante, Alicante

All Listed Sponsors
collaborator

Merck, S.L., Spain

INDUSTRY

collaborator

Syntax for Science, S.L

INDUSTRY

collaborator

Fundación IVI

OTHER

lead

Instituto Valenciano de Infertilidad, IVI Alicante

OTHER

NCT03741699 - Recombinant LH Prior to Ovarian Stimulation in Poor Ovarian Responders (PRE-LH) | Biotech Hunter | Biotech Hunter